Success Metrics

Clinical Success Rate

66.7%

Based on 6 completed trials

Completion Rate

67%(6/9)

Active Trials

7(44%)

Results Posted

183%(11 trials)

Terminated

3(19%)

Phase Distribution

Ph phase_1

31%

Ph phase_2

50%

Ph phase_3

19%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution16 total trials

Phase 1Safety & dosage

5(31.3%)

Phase 2Efficacy & side effects

8(50.0%)

Phase 3Large-scale testing

3(18.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(7)

Completed(6)

Terminated(3)

Detailed Status

Active, not recruiting7

Completed6

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 15 (31.3%)

Phase 28 (50.0%)

Phase 33 (18.8%)

Trials by Status

completed638%

active_not_recruiting744%

terminated319%

Recent Activity

7 active trials

Showing 5 of 16

active_not_recruitingphase_3

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02443077

active_not_recruitingphase_3

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02048813

active_not_recruitingphase_2

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

NCT02581930

active_not_recruitingphase_1

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

NCT01012817

active_not_recruitingphase_1

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT02453620

View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials

NCT02443077Phase 3

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Active Not Recruiting

NCT02048813Phase 3

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active Not Recruiting

NCT02581930Phase 2

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Active Not Recruiting

NCT01012817Phase 1

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Active Not Recruiting

NCT02453620Phase 1

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Active Not Recruiting

NCT01267955Phase 2

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Active Not Recruiting

NCT02399371Phase 2

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Active Not Recruiting

NCT02717507Phase 2

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Completed

NCT00381641Phase 2

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery